Xishuangbanna Puerh (Camellia sinensis)

Xishuangbanna Puerh is a post-fermented tea (Camellia sinensis) produced in Yunnan, China, containing bioactive compounds including gallocatechin gallate, theabrownin, and microbially transformed polyphenols. Theabrownin, a high-molecular-weight pigment formed during wet-pile fermentation, is thought to modulate lipid metabolism by inhibiting pancreatic lipase activity and altering gut microbiota composition.

Origin & History

Xishuangbanna Puerh is a raw (sheng) Pu-erh tea cultivar variant of Camellia sinensis var. assamica, sourced from the Xishuangbanna region in Yunnan Province, China. It is produced from sun-dried, minimally processed leaves that undergo post-fermentation aging, developing unique chemical profiles including theabrownins (10.46-14.91%), thearubigins (3.24-4.76%), and various polyphenols.

Historical & Cultural Context

Pu-erh tea, including Xishuangbanna variants, has centuries of use in Chinese traditional medicine as a digestive aid, lipid-lowering agent, and general health tonic. Originating in Yunnan, China, raw Pu-erh (sheng) types like Xishuangbanna are particularly valued for their aging potential and unique aroma from post-fermentation processing.

Health Benefits

• Antioxidant effects from polyphenols like gallocatechin gallate and theabrownin (preliminary evidence only)
• Traditional use as a digestive aid (historical use, no clinical trials)
• Traditional lipid-lowering properties (historical use, no clinical trials)
• General health tonic properties (traditional use only)
• Potential bioactivities from catechins and gallic acid (preclinical evidence only)

How It Works

Theabrownin, the dominant polyphenol complex in fermented Puerh, inhibits pancreatic lipase, reducing dietary fat hydrolysis and subsequent triglyceride absorption in the small intestine. Gallocatechin gallate scavenges reactive oxygen species by donating hydrogen atoms to free radicals, modulating NF-κB signaling to reduce pro-inflammatory cytokine expression. Microbial fermentation during the wo dui (wet-pile) process also generates bioavailable metabolites that may modulate short-chain fatty acid production and Bacteroidetes-to-Firmicutes ratios in the gut microbiome.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found for Xishuangbanna Puerh or Pu-erh tea in general. Current research focuses primarily on chemical analysis and composition studies rather than clinical outcomes, with only preclinical or tentative bioactivity data available.

Clinical Summary

Human clinical evidence specific to Xishuangbanna Puerh is largely absent; most data derive from broader Puerh tea research or in vitro and rodent studies. A small randomized controlled trial on general Puerh tea (n=86, 12 weeks) reported modest reductions in LDL cholesterol (~5–8%) and total triglycerides (~10%) compared to control, though methodological limitations restrict generalizability. Animal studies using theabrownin isolates demonstrated dose-dependent inhibition of hepatic lipogenesis via downregulation of SREBP-1c, but equivalent human dosing remains undefined. No registered clinical trials specifically targeting Xishuangbanna cultivar effects on human endpoints have been identified as of 2024.

Nutritional Profile

Xishuangbanna Puerh (Camellia sinensis) is consumed primarily as a brewed tea, so nutritional content reflects both dry leaf composition and typical infusion yield. Dry leaf contains: Polyphenols (18–35% of dry weight), dominated by catechins including EGCG (5–15%), EGC (3–8%), ECG (2–6%), EC (1–4%), and gallocatechin gallate; post-fermentation oxidation converts catechins into theabrownins (estimated 15–25% of dry weight in aged puerh) and theaflavins. Gallic acid present at approximately 0.5–2% dry weight. Caffeine: 2–4% dry weight (approximately 30–60mg per 200ml brewed cup). Theobromine: ~0.1–0.2% dry weight. Protein: 20–30% dry weight in leaf (largely insoluble, minimal extraction into brew, <1g per cup). Carbohydrates: 40–50% dry weight (primarily structural polysaccharides; water-soluble polysaccharides ~3–7% extractable, approximately 100–200mg per cup). Dietary fiber: high in dry leaf (~30–40% dry weight) but negligible in brewed infusion. Fat: <1% dry weight. Minerals per brewed cup (200ml): Fluoride 0.1–0.5mg, Manganese 0.3–0.6mg (~15–30% DV), Potassium 20–40mg, Magnesium 2–5mg, Zinc 0.1–0.3mg, Calcium 2–8mg. Vitamins: trace Vitamin K (~5–10mcg per 100g dry leaf), minimal B-vitamins (B2 ~0.3mg/100g dry leaf; minimal in infusion). Theanine (L-theanine): 1–2% dry weight, approximately 20–40mg per brewed cup (notable bioavailability, crosses blood-brain barrier). Bioavailability notes: Catechin bioavailability from puerh is lower than green tea due to fermentation-induced oxidation; theabrownins are large polymeric compounds with limited systemic absorption but may exert local gut effects. Theanine and caffeine are highly bioavailable from infusion (~80–90% extraction). Mineral bioavailability may be reduced by polyphenol binding, particularly for iron and zinc. Aged/fermented puerh contains detectable levels of lovastatin-related compounds from microbial activity (estimated <1mg/g dry leaf, variable by fermentation batch).

Preparation & Dosage

No clinically studied dosage ranges are available for Xishuangbanna Puerh in any form (extracts, powder, or standardized preparations). Studies have focused on chemical analysis rather than therapeutic dosing. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Green tea extract, L-theanine, Rhodiola rosea, Ginkgo biloba, Quercetin

Safety & Interactions

Xishuangbanna Puerh contains caffeine (approximately 30–70 mg per 8 oz serving depending on steep time), which may exacerbate anxiety, insomnia, or tachycardia in sensitive individuals or at high consumption levels. Its polyphenol content can chelate non-heme iron and reduce absorption by up to 50–70% when consumed with meals, posing a risk for individuals with iron-deficiency anemia. Theabrownin may potentiate the effects of lipid-lowering medications such as statins, though direct pharmacokinetic interaction data are lacking; caution is advised when combining with anticoagulants like warfarin due to potential vitamin K interference from tea compounds. Pregnant and breastfeeding individuals should limit intake to moderate levels consistent with general caffeine guidelines (under 200 mg/day total), and those with hepatic conditions should consult a physician given rare reports of hepatotoxicity associated with concentrated tea extracts.